IQV IQVIA Holdings, Inc. Common Stock
Про IQVIA Holdings, Inc. Common Stock Огляд компанії з Wikipedia
IQVIA Holdings, Inc. is an American health information technology and clinical research company headquartered in Durham, North Carolina. The company provides clinical research services, healthcare analytics, technology solutions, and commercial outsourcing services to pharmaceutical, biotechnology, medical device, and healthcare organizations worldwide.
Детальніше
IQVIA Holdings, Inc. is an American health information technology and clinical research company headquartered in Durham, North Carolina. The company provides clinical research services, healthcare analytics, technology solutions, and commercial outsourcing services to pharmaceutical, biotechnology, medical device, and healthcare organizations worldwide.
IQVIA operates through three business segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Through its technology and analytics business, the company maintains access to more than one billion supposedly anonymized patient records globally, and provides healthcare data, analytics, and software services to life science organizations, health care centers like hospitals, and pharmacists worldwide. This participates in extending their access to personal health data around the globe.
The company was formed in 2016 through the merger of Quintiles, a contact research organization, and IMS Health, a healthcare data and analytics provider. The combined company operated as QuintilesIMS before adopting the name IQVIA in 2017. The IQVIA name is a combination of: I (IMS Health), Q (Quintiles), and VIA (by way of).
History
The company operates three divisions: Technology & Analytics (40% of 2024 revenues), focused on health information technology with access to 1.2 billion unique non-identified patient records globally, offers cloud-based customer relationship management application software as well as analytics consulting services all to the healthcare industry; Research & Development (55% of 2024 revenues), which is a contract research organization that handles all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, post-approval services, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics; and Contract Sales & Medical (5% of 2024 revenues), which offers contract sales to healthcare providers and patient engagement services.
IMS Health
The original name of the company was Intercontinental Marketing Statistics, hence the IMS name. IMS Health's corporate headquarters is located in Danbury, Connecticut, United States. The company's chairman and CEO is Ari Bousbib.
In 1998, the parent company, Cognizant Corporation, split into two companies: IMS Health and Nielsen Media Research. After this restructuring, Cognizant Technology Solutions became a public subsidiary of IMS Health
In 2002, IMS Health acquired Cambridge Pharma Consultancy, a privately held international firm that provides strategic advice to pharmaceutical management.
In 2002, IMS Health acquired the Rosenblatt Klauber Group, a privately held international consultancy that provides forecasting, opportunity assessment & management development services to pharmaceutical companies.
In 2003, acquired Marketing Initiatives, a specialist in healthcare facility profile data, and Data Niche Associates, a provider of rebate validation services for Medicaid and managed care. In 2003, IMS Health sold its entire 56% stake in Cognizant and both companies are separated into two independent entities as IMS Health and Cognizant
In 2004, United Research China Shanghai was acquired, providing coverage of China's consumer health market.
In 2005, acquired PharMetrics, a U.S. provider of patient-centric integrated claims data.
In 2006, acquired the Life Sciences practice of Strategic Decisions Group, a portfolio strategy consultant to the life sciences industry.
In 2007, IMS Health acquired IHS and MedInitiatives, providers of healthcare data management analytics and technology services. That same year, ValueMedics Research was acquired, extending IMS Health's health economics and outcomes research capabilities.
In 2007, ranked in the Businessweek 50. This list represents "best in class" companies from the ten economic sectors that make up the S&P 500.
In 2008, named to the World's Most Admired Companies list by Fortune. The company received the recognition again in 2010.
In 2008, acquired RMBC, a provider of national pharmaceutical market intelligence and analytics in Russia.
In 2008, acquired the Skura professional services group, based out of Mississauga, Ontario, Canada and specialized in data integration, consulting and services in business intelligence platforms to pharmaceutical and healthcare clients in North America and Europe.
In 2009, named to the Dow Jones Sustainability North America Index in recognition of the company's economic, environmental and social performance among the largest 600 North American companies.
In February 2010, IMS Health was taken private by TPG Capital, CPP Investment Board, and Leonard Green & Partners.
In 2010, acquired Brogan, Inc., a privately held market research and consulting firm serving the Canada healthcare market.
In 2011, expanded its specialty and patient-level data assets in the United States with the acquisition of SDI Health. Also that year, the company acquired Ardentia Ltd in the UK, and Med-Vantage in the United States to build on its payer services in those markets.
In 2012, acquired PharmARC Analytic Solutions Pvt. Ltd, a Bangalore-based analytics company.
In 2012, acquired DecisionView, a software solutions company that helps life sciences organizations plan and track patient enrollment for clinical trials and TTC, a benchmarking solutions and analytics company that helps clients plan for and negotiate the costs of clinical trials. Also in 2012, the company purchased PharmaDeals Ltd., a provider of online information about business transactions, licensing, and mergers and acquisitions activity within the pharmaceutical industry.
In 2013, acquired several companies to expand its portfolio of SaaS products: Incential Software, a provider of sales performance management technology services; 360 Vantage, which delivers multi-channel CRM software capabilities; Appature, which offers a relationship marketing platform; and Semantelli, a provider of social media analytics for the global healthcare industry.
In May 2015, IMS increased its software development capability by acquiring Dataline Software Ltd, a bespoke software development company and big data research specialist in the UK.
In April 2015, IMS Health completed the purchase of Cegedim's Customer Relationship Management (CRM) software and Strategic Data business for €396 million. Cegedim acquired the software and related business when it purchased Dendrite International in 2007.
In August 2015, IMS Health completed the purchase of Boston Biomedical Consultants, a provider of market data and market research covering the in vitro Diagnostics market
In May 2016, the company announced it would merge with Quintiles IMS Health shareholders received 0.384 shares of Quintiles common stock for each share of IMS Health common stock they held, leaving the split of ownership at 51.4% IMS and 48.6% Quintiles. The merger was completed in October and the resulting company was a $17.6 billion company called QuintilesIMS.
On November 6, 2017, the company adopted the new name of IQVIA.
Quintiles
Quintiles was the world's largest provider of biopharmaceutical development and commercial outsourcing services. The company offered clinical data management, clinical trial execution services, pharmaceuticals, drug development, financial partnering, and commercialization expertise to companies in the biotechnology, pharmaceutical and healthcare sectors.
In 1982, Dennis Gillings founded and incorporated Quintiles Transnational in North Carolina. Quintiles Transnational established Quintiles Pacific Inc. and Quintiles Ireland Ltd. in 1990. In 1991 Quintiles GmbH was established in Germany and Quintiles Laboratories Ltd. was established in Atlanta, Georgia. In September 1996, Quintiles purchased Innovex Ltd. of Britain for $747.5 million in stock. Quintiles went public in 1997 and completed a successful secondary stock offering.
In 1974, Dennis Gillings signs the first contract to provide statistical and data management consulting for pharmaceutical clients.
In 1982, Quintiles, Inc., is incorporated in North Carolina.
In 1990, Quintiles Pacific Inc. and Quintiles Ireland Ltd. are established.
In 1991, Quintiles GmbH is established in Germany; Quintiles Laboratories Ltd. is established in Atlanta, Georgia.
In 1996, Quintiles buys Innovex Ltd. and BRI International Inc., becoming the world's largest CRO.
In 1997, Quintiles goes public, completing a successful secondary stock offering.
In 1998, Quintiles becomes the first company in the industry to break the $1 billion mark, when it reports net revenues of $1.19 billion.
In 1999, the company joins the S&P 500 Index.
In 2003, the Board of Directors agrees to merge with Pharma Services Holdings Inc; Quintiles becomes a private company.
In 2009, Quintiles opens new corporate headquarters in Durham, North Carolina.
In 2010, Quintiles opens new European headquarters in the UK and establishes operations in East Africa.
In 2011, Quintiles buys Advion Biosciences, a bioanalytical lab based out of Ithaca, New York.
In 2013, Quintiles filed for an IPO on 15 February in order to go public again; Quintiles begins trading on the New York Stock Exchange (NYSE) under ticker symbol Q."
Merger of IMS Health and Quintiles
In October 2016, Quintiles merged with IMS Health to form QuintilesIMS. In November 2017, the company adopted the new name of IQVIA.
The company is ranked 282nd on the Fortune 500 and 680th on the Forbes Global 2000.
Controversies
IMS Health's business of collecting and selling pharmaceutical sales data, even though they say it is anonymized, was under scrutiny from both the media and the legal system.
IMS Health v. Ayotte was a free speech case involving IMS Health.
Sorrell v. IMS Health Inc. was a case about physician-data privacy, which went to the U.S. Supreme Court. The court ruled in favor of the company.
IQVIA was contracted by the UK government's Office of National Statistics to provide data on the prevalence of COVID-19 infection in the population. Some users of the survey reported problems contacting IQVIA and arranging for testing. The problems with how the survey results were collected were criticised for potentially leading to biased data by New Scientist.
On July 17, 2023, the Federal Trade Commission sued to block IQVIA’s acquisition of Propel Media alleging in an administrative complaint that the acquisition would give IQVIA a market-leading position in health care programmatic advertising and would raise health-care prices for consumers. In December 2023, U.S. District Court Judge Edgardo Ramos issued an order granting the FTC’s motion for preliminary injunction to block the merger. Speaking in favor of the FTC, Ramos said, "The FTC has shown that there is a reasonable probability that the proposed acquisition will substantially impair competition in the relevant market and that the equities weigh in favor of injunctive relief." An administrative trial was scheduled to start on January 18, 2024. However, on January 5, 2024, IQVIA and Propel Media announced that they had mutually agreed to abandon the proposed merger.
Джерело: Wikipedia (Англійська), CC BY-SA 4.0 · Переглянути на Wikipedia ↗
IQV Знімок акцій Ціна, ринкова капіталізація, P/E, EPS, ROE, борг/власний капітал, діапазон 52 тижнів
IQV Графік ціни акцій Денні OHLCV з технічними індикаторами — панування, масштабування та налаштування вашого представлення
10-річна ефективність Тренди виручки, чистого прибутку, маржі та EPS
Оцінка Співвідношення P/E, P/S, P/B, EV/EBITDA — акція дорога чи дешева?
Прибутковість Валова, операційна та чиста маржа; ROE, ROA, ROIC
Фінансове здоровʼя Борг, ліквідність, платоспроможність — міцність балансу
Зростання Зростання виручки, EPS та чистого прибутку: рік до року, 3-річний CAGR, 5-річний CAGR
Ефективність капіталу Оборотність активів, оборотність запасів, оборотність дебіторської заборгованості
IQV Консенсус аналітиків Бичачі та ведмежі думки аналітиків, 12-місячна цільова ціна, потенціал зростання
- Активна купівля 8 28,6%
- Купівля 14 50,0%
- Утримувати 6 21,4%
- Продаж 0 0,0%
- Активний продаж 0 0,0%
12-місячна цільова ціна
18 аналітиків · 2026-08-17Історія прибутків EPS фактичний проти прогнозу, сюрприз %, коефіцієнт перевищення, дата наступного звіту про прибутки
| Період | EPS Actual | EPS прогноз | Сюрприз |
|---|---|---|---|
| 30 червня 2026 р. | $3.15 | $3.06 | 0.09% |
| 31 березня 2026 р. | $2.90 | $2.85 | 0.05% |
| 31 грудня 2025 р. | $3.42 | $3.43 | -0.01% |
| 30 вересня 2025 р. | $3.00 | $3.00 | -0.00% |
| 30 червня 2025 р. | $2.81 | $2.80 | 0.01% |
| 31 березня 2025 р. | $2.70 | $2.66 | 0.04% |
Порівняння з аналогами (підгалузь GICS) Ключові показники порівняно з аналогами в секторі
| Тікер | Капіталізація | P/E | Виручка рік до року | Чиста маржа | ROE | Валова маржа |
|---|---|---|---|---|---|---|
| IQV | $38.23B | 28.8 | 5.9% | 8.3% | 21.6% | — |
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | — |
| DHR | $161.82B | 45.3 | 2.9% | 14.7% | 7.1% | 59.1% |
| A | $41.43B | 32.0 | 6.7% | 18.8% | 20.6% | — |
| WAT | $22.62B | 35.3 | 7.0% | 20.3% | 27.2% | — |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | — |
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
Повні фундаментальні показники Усі показники за роками — звіт про прибутки та збитки, баланс, рух грошових коштів
Звіт про прибутки та збитки 16
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B | $11.36B | $11.09B | $10.41B | $9.70B | $6.82B | $5.74B | $5.46B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $4.62B | $3.24B | $2.71B | $2.66B | |
| R&D Expense | · | · | · | · | · | · | · | · | · | · | $3M | $6M | |
| SG&A Expense | $2.00B | $1.99B | $2.05B | $2.07B | $1.96B | $1.79B | $1.73B | $1.72B | $1.62B | $1.02B | $815M | $781M | |
| Operating Income | $2.18B | $2.20B | $1.98B | $1.80B | $1.39B | $731M | $777M | $741M | $665M | $576M | $646M | $590M | |
| Interest Expense | $729M | $670M | $672M | $416M | $375M | $416M | $447M | $414M | $346M | $144M | $101M | $101M | |
| Interest Income | $45M | $47M | $36M | $13M | $6M | $6M | $9M | $8M | $7M | $4M | $4M | $4M | |
| Other Non-op | $99M | $90M | $124M | $-33M | $130M | $65M | $37M | $-5M | $-13M | $11M | $-2M | $8M | |
| Pretax Income | $1.59B | $1.67B | $1.46B | $1.36B | $1.13B | $373M | $352M | $328M | $294M | $416M | $539M | $501M | |
| Income Tax | $252M | $301M | $101M | $260M | $163M | $72M | $116M | $59M | $-992M | $325M | $159M | $149M | |
| Net Income | $1.36B | $1.37B | $1.36B | $1.09B | $966M | $279M | $191M | $259M | $1.28B | $72M | $387M | $357M | |
| EPS (Basic) | $7.91 | $7.57 | $7.39 | $5.82 | $5.05 | $1.46 | $0.98 | $1.27 | $5.86 | $0.48 | $3.15 | $2.78 | |
| EPS (Diluted) | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 | $1.43 | $0.96 | $1.24 | $5.74 | $0.47 | $3.08 | $2.72 | |
| Shares (Basic) | 171,900,000 | 181,300,000 | 183,800,000 | 187,600,000 | 191,400,000 | 191,300,000 | 195,100,000 | 203,700,000 | 217,800,000 | 149,100,000 | 123,000,000 | 128,000,000 | |
| Shares (Diluted) | 173,500,000 | 183,400,000 | 186,300,000 | 190,600,000 | 195,000,000 | 195,000,000 | 199,600,000 | 208,200,000 | 222,600,000 | 152,000,000 | 125,600,000 | 131,100,000 | |
| EBITDA | $3.33B | $3.32B | $3.10B | $2.93B | $2.66B | $2.02B | $1.98B | $1.88B | $1.73B | $931M | $774M | $711M |
Баланс 28
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.98B | $1.70B | $1.38B | $1.22B | $1.37B | $1.81B | $837M | $891M | $959M | $1.20B | $977M | $867M | |
| Short-term Investments | $161M | $141M | $120M | $93M | $111M | $88M | $62M | $47M | $46M | $40M | · | · | |
| Receivables | $3.40B | $3.20B | $3.38B | $2.92B | $2.55B | $2.41B | $2.58B | $2.39B | $2.10B | $1.71B | $1.17B | $975M | |
| Prepaid Expense | $162M | $154M | $141M | $151M | $156M | $159M | $138M | $151M | $146M | $123M | $51M | $45M | |
| Other Current Assets | · | · | · | · | · | · | · | $322M | $259M | $235M | $83M | $92M | |
| Current Assets | $6.25B | $5.83B | $5.60B | $4.98B | $4.76B | $5.09B | $4.13B | $3.87B | $3.55B | $3.34B | $2.41B | $2.15B | |
| PP&E (Net) | $533M | $535M | $523M | $532M | $497M | $482M | $458M | $434M | $440M | $406M | $188M | $190M | |
| PP&E (Gross) | $1.44B | $1.35B | $1.33B | $1.37B | $1.26B | $1.16B | $1.05B | $1.00B | $923M | $769M | $510M | $496M | |
| Accum. Depreciation | $905M | $819M | $803M | $840M | $765M | $673M | $597M | $567M | $483M | $363M | $322M | $306M | |
| Goodwill | $16.62B | $14.71B | $14.57B | $13.92B | $13.30B | $12.65B | $12.16B | $11.80B | $11.85B | $10.73B | $720M | $464M | |
| Intangibles | $4.96B | $4.50B | $4.84B | $4.82B | $4.94B | $5.21B | $5.51B | $5.95B | $6.59B | $6.39B | $368M | $280M | |
| Total Assets | $29.94B | $26.90B | $26.68B | $25.34B | $24.69B | $24.56B | $23.25B | $22.55B | $22.86B | $21.21B | $3.93B | $3.30B | |
| Accounts Payable | · | · | · | · | · | · | · | $437M | $322M | $250M | $145M | $109M | |
| Accrued Liabilities | $2.97B | $2.95B | $2.85B | $2.67B | $2.36B | $2.23B | $1.94B | $1.86B | $1.66B | $1.49B | $761M | $734M | |
| Current Liabilities | $8.34B | $6.96B | $6.49B | $5.58B | $5.24B | $4.56B | $3.94B | $3.53B | $3.16B | $2.71B | $1.59B | $1.47B | |
| Capital Leases | $225M | $173M | $223M | $264M | $313M | $371M | $396M | · | · | · | $18.0K | $14.0K | |
| Deferred Tax | $179M | $196M | $202M | $464M | $410M | $338M | $646M | $627M | $786M | $2.04B | · | $62M | |
| Other Non-current Liabilities | $688M | $668M | $698M | $671M | $649M | $633M | $456M | $418M | $440M | $402M | $183M | $184M | |
| Total Liabilities | $23.31B | $20.83B | $20.57B | $19.57B | $18.65B | $18.28B | $16.99B | $15.60B | $14.61B | $12.35B | $4.26B | $4.00B | |
| Long-term Debt | $15.72B | $13.98B | $13.67B | $12.75B | $12.12B | $12.53B | $11.64B | $11.01B | $10.27B | $7.22B | $2.50B | $2.31B | |
| Total Debt | $15.72B | $13.98B | $13.67B | $12.75B | $12.12B | $12.53B | $11.64B | $11.01B | $10.22B | $7.20B | $2.47B | $2.29B | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | $144M | |
| Retained Earnings | $7.42B | $6.07B | $4.69B | $3.33B | $2.24B | $1.28B | $998M | $807M | $538M | $-399M | $-462M | $-789M | |
| Treasury Stock | $11.36B | $10.10B | $8.74B | $7.74B | $6.57B | $6.17B | $5.73B | $4.77B | $3.37B | $1.00B | · | · | |
| AOCI | $-943M | $-1.04B | $-867M | $-727M | $-406M | $-205M | $-311M | $-224M | $49M | $-570M | $-111M | $-59M | |
| Stockholders' Equity | $6.50B | $6.07B | $6.11B | $5.76B | $6.04B | $6.28B | $6.26B | $6.71B | $8.00B | $8.63B | $-564M | $-704M | |
| Liabilities + Equity | $29.94B | $26.90B | $26.68B | $25.34B | $24.69B | $24.56B | $23.25B | $22.55B | $22.86B | $21.21B | $3.93B | $3.30B | |
| Shares Outstanding | 169,600,000 | 258,200,000 | 257,200,000 | 256,400,000 | 255,800,000 | 254,700,000 | 253,000,000 | 251,500,000 | 249,500,000 | 248,300,000 | 119,400,000 | 124,100,000 |
Грошовий потік 16
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1.14B | $1.11B | $1.12B | $1.13B | $1.26B | $1.29B | $1.20B | $1.14B | $1.01B | $289M | $128M | $121M | |
| Stock-based Comp | $247M | $206M | $217M | $194M | $170M | $95M | $146M | $113M | $106M | $106M | $38M | $30M | |
| Deferred Tax | $-180M | $-129M | $-269M | $-115M | $-138M | $-176M | $-157M | $-177M | $-1.22B | $115M | $18M | $-6M | |
| Amort. of Intangibles | $984M | $965M | $974M | $970M | $1.12B | $1.15B | $1.07B | $1.02B | $886M | $210M | $67M | $58M | |
| Restructuring | $105M | $67M | $84M | $28M | $20M | $52M | $75M | $68M | $63M | $71M | $30M | $9M | |
| Other Non-cash | $83M | $152M | $-282M | $-40M | $680M | $474M | $35M | $-82M | $-240M | $241M | $-95M | $-69M | |
| Operating Cash Flow | $2.65B | $2.72B | $2.15B | $2.26B | $2.94B | $1.96B | $1.42B | $1.25B | $970M | $860M | $476M | $433M | |
| CapEx | $603M | $602M | $649M | $674M | $640M | $616M | $582M | $459M | $369M | $164M | $78M | $83M | |
| Investing Cash Flow | $-2.31B | $-1.44B | $-1.60B | $-2.01B | $-2.10B | $-796M | $-1.19B | $-810M | $-1.19B | $1.73B | · | · | |
| Stock Repurchased | $1.24B | $1.35B | $992M | $1.17B | $406M | $447M | $949M | $1.41B | $2.62B | $1.10B | $515M | $415M | |
| Net Stock Activity | $-1.24B | $-1.35B | $-992M | $-1.17B | $-406M | $-447M | $-949M | $-1.41B | $-2.62B | $-1.10B | $-515M | $-415M | |
| Financing Cash Flow | $-150M | $-878M | $-382M | $-329M | $-1.24B | $-217M | $-276M | $-452M | $-72M | $-2.28B | · | · | |
| Net Change in Cash | $278M | $326M | $160M | $-150M | $-448M | $977M | $-54M | $-68M | $-239M | $221M | $110M | $90M | |
| Taxes Paid | · | $295M | $340M | $255M | $222M | $209M | $215M | $211M | $195M | $106M | $121M | $139M | |
| Free Cash Flow | $2.05B | $2.11B | $1.50B | $1.59B | $2.30B | $1.34B | $835M | $795M | $601M | $696M | $397M | $349M | |
| Levered FCF | $1.44B | $1.56B | $875M | $1.25B | $1.98B | $1.01B | $535M | $455M | $-777M | $656M | $326M | $420M |
Прибутковість 7
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.4% | 14.3% | 13.2% | 12.5% | 10.0% | 6.4% | 7.0% | 7.1% | 7.4% | 9.3% | 11.3% | 10.8% | |
| Net Margin | 8.3% | 8.9% | 9.1% | 7.6% | 7.0% | 2.5% | 1.7% | 2.5% | 13.4% | 1.7% | 6.8% | 6.5% | |
| Pretax Margin | 9.8% | 10.8% | 9.7% | 9.5% | 8.1% | 3.3% | 3.2% | 3.1% | 3.4% | 7.0% | 9.4% | 9.2% | |
| EBITDA Margin | 20.4% | 21.5% | 20.7% | 20.3% | 19.1% | 17.8% | 17.8% | 18.1% | 17.8% | 13.5% | 13.5% | 13.0% | |
| ROA | 4.8% | 5.1% | 5.2% | 4.4% | 3.9% | 1.2% | 0.83% | 1.1% | 6.0% | 0.92% | 10.7% | 11.2% | |
| ROE | 21.6% | 22.6% | 22.9% | 18.5% | 15.7% | 4.5% | 3.0% | 3.5% | 15.6% | 2.9% | -61.1% | -52.0% | |
| ROIC | 8.3% | 9.0% | 9.3% | 7.9% | 6.6% | 3.2% | 2.9% | 3.4% | 15.6% | 1.1% | 23.9% | 26.1% |
Ліквідність та платоспроможність 5
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.7 | 0.8 | 0.9 | 0.9 | 0.9 | 1.1 | 1.0 | 1.1 | 1.2 | 1.2 | 1.5 | 1.5 | |
| Quick Ratio | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | 1.0 | 1.1 | 1.3 | 1.3 | |
| Debt / Equity | 2.4 | 2.3 | 2.2 | 2.2 | 2.0 | 2.1 | 1.9 | 1.6 | 1.3 | 0.8 | -4.4 | -3.3 | |
| LT Debt / Equity | 2.1 | 2.1 | 2.1 | 2.2 | 2.0 | 2.1 | 1.9 | 1.6 | 1.2 | 0.8 | -4.3 | -3.3 | |
| Interest Coverage | 3.0 | 3.3 | 2.9 | 4.3 | 3.7 | 1.8 | 1.7 | 1.8 | 2.1 | 4.5 | 6.4 | -5.9 |
Ефективність 2
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | 0.4 | 0.5 | 1.6 | 1.7 | |
| Receivables Turnover | 4.9 | 4.7 | 4.8 | 5.3 | 5.6 | 4.6 | 4.5 | 4.6 | 5.3 | 4.8 | 5.4 | 5.7 |
Темпи зростання 9
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 5.9% | 2.8% | 4.0% | 3.9% | 22.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 4.2% | 3.5% | 9.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 7.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 4.7% | 2.7% | 27.5% | 15.6% | 246.2% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 11.1% | 14.8% | 72.1% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 40.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -0.95% | 1.1% | 24.5% | 12.9% | 246.2% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 7.6% | 12.4% | 69.5% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · | · |
Оцінка (TTM) 13
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B | $11.36B | $11.09B | $10.41B | $9.70B | $6.82B | $5.74B | $5.46B | |
| Net Income TTM | $1.36B | $1.37B | $1.36B | $1.09B | $966M | $279M | $191M | $259M | $1.28B | $72M | $387M | $357M | |
| Market Cap | $38.23B | $34.61B | $42.00B | $38.05B | $53.78B | $34.26B | $29.71B | $29.22B | $24.43B | $18.88B | $8.20B | $7.31B | |
| Enterprise Value | $51.81B | $46.75B | $54.17B | $49.49B | $64.42B | $44.89B | $40.46B | $39.29B | $33.65B | $24.85B | $9.69B | $8.73B | |
| P/E | 28.8 | 26.2 | 31.7 | 35.8 | 57.0 | 125.3 | 160.9 | 93.7 | 17.1 | 161.8 | 22.3 | 21.6 | |
| P/S | 2.3 | 2.2 | 2.8 | 2.6 | 3.9 | 3.0 | 2.7 | 2.8 | 2.5 | 2.8 | 1.4 | 1.3 | |
| P/B | 5.9 | 5.7 | 6.9 | 6.6 | 8.9 | 5.7 | 4.9 | 4.4 | 3.0 | 2.2 | -14.5 | -10.4 | |
| P / Cash Flow | 14.4 | 12.7 | 19.5 | 16.8 | 18.3 | 17.5 | 21.0 | 23.3 | 25.2 | 22.0 | 17.2 | 16.9 | |
| P / FCF | 18.6 | 16.4 | 28.0 | 24.0 | 23.4 | 25.5 | 35.6 | 36.8 | 40.6 | 27.1 | 20.6 | 20.9 | |
| EV / EBITDA | 15.6 | 14.1 | 17.5 | 16.9 | 24.2 | 22.2 | 20.4 | 20.9 | 19.4 | 26.7 | 12.5 | 12.3 | |
| EV / FCF | 25.3 | 22.1 | 36.1 | 31.2 | 28.0 | 33.4 | 48.5 | 49.4 | 56.0 | 35.7 | 24.4 | 25.0 | |
| EV / Revenue | 3.2 | 3.0 | 3.6 | 3.4 | 4.6 | 4.0 | 3.6 | 3.8 | 3.5 | 3.6 | 1.7 | 1.6 | |
| Earnings Yield | 3.5% | 3.8% | 3.1% | 2.8% | 1.8% | 0.80% | 0.62% | 1.1% | 5.9% | 0.62% | 4.5% | 4.6% |
Звіт про прибутки та збитки 15
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.37B | $4.15B | $4.36B | $4.10B | $4.02B | $3.83B | $3.96B | $3.90B | $3.81B | $3.74B | $3.87B | $3.74B | $3.73B | $3.65B | $3.74B | $3.56B | |
| Gross Profit | · | · | · | · | · | · | · | $915M | $863M | $827M | · | $862M | $850M | $802M | · | $812M | |
| SG&A Expense | $574M | $502M | $468M | $514M | $509M | $508M | $453M | $522M | $509M | $508M | $556M | $502M | $482M | $513M | $583M | $517M | |
| Operating Income | $506M | $514M | $627M | $553M | $506M | $496M | $626M | $550M | $520M | $506M | $501M | $481M | $524M | $471M | $379M | $472M | |
| Interest Expense | $197M | $192M | $193M | $189M | $182M | $165M | $171M | $170M | $163M | $166M | $181M | $181M | $169M | $141M | $128M | $108M | |
| Interest Income | $7M | $10M | $11M | $13M | $10M | $11M | $11M | $13M | $12M | $11M | $12M | $14M | $4M | $6M | $6M | $4M | |
| Other Non-op | $-12M | $-4M | $94M | $31M | $-11M | $-15M | $78M | $-44M | $67M | $-11M | $47M | $35M | $16M | $26M | $18M | $-8M | |
| Pretax Income | $301M | $328M | $537M | $408M | $323M | $323M | $544M | $349M | $436M | $340M | $373M | $349M | $375M | $362M | $275M | $360M | |
| Income Tax | $60M | $59M | $59M | $76M | $56M | $61M | $112M | $65M | $75M | $49M | $-102M | $51M | $81M | $71M | $48M | $70M | |
| Net Income | $256M | $274M | $514M | $331M | $266M | $249M | $437M | $285M | $363M | $288M | $469M | $303M | $297M | $289M | $227M | $283M | |
| EPS (Basic) | $1.54 | $1.63 | $3.00 | $1.94 | $1.55 | $1.42 | $2.43 | $1.57 | $1.99 | $1.58 | $2.56 | $1.66 | $1.61 | $1.56 | $1.23 | $1.52 | |
| EPS (Diluted) | $1.53 | $1.61 | $2.97 | $1.93 | $1.54 | $1.40 | $2.41 | $1.55 | $1.97 | $1.56 | $2.54 | $1.63 | $1.59 | $1.53 | $1.21 | $1.49 | |
| Shares (Basic) | 166,100,000 | 168,400,000 | -345,800,000 | 170,200,000 | 171,800,000 | 175,700,000 | -364,900,000 | 182,100,000 | 182,200,000 | 181,900,000 | -369,300,000 | 182,900,000 | 184,400,000 | 185,800,000 | -377,200,000 | 186,500,000 | |
| Shares (Diluted) | 167,300,000 | 169,800,000 | -348,800,000 | 171,700,000 | 173,200,000 | 177,400,000 | -369,400,000 | 184,200,000 | 184,300,000 | 184,300,000 | -374,500,000 | 185,500,000 | 186,700,000 | 188,600,000 | -383,300,000 | 189,400,000 | |
| EBITDA | $798M | $802M | · | $839M | $782M | $761M | · | $828M | $789M | $770M | · | $778M | $783M | $724M | · | $720M |
Баланс 25
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.91B | $1.95B | $1.98B | $1.81B | $2.04B | $1.74B | $1.70B | $1.57B | $1.54B | $1.44B | · | $1.22B | $1.38B | $1.49B | · | $1.27B | |
| Short-term Investments | $171M | $156M | $161M | $158M | $149M | $136M | $141M | $140M | $133M | $131M | · | $108M | $110M | $104M | · | $87M | |
| Receivables | $3.35B | $3.35B | $3.40B | $3.27B | $3.34B | $3.27B | $3.20B | $3.20B | $3.25B | $3.43B | · | $3.23B | $3.14B | $3.06B | · | $2.64B | |
| Prepaid Expense | $220M | $167M | $162M | $177M | $200M | $166M | $154M | $195M | $191M | $173M | · | $177M | $179M | $165M | · | $176M | |
| Current Assets | $6.23B | $6.22B | $6.25B | $5.98B | $6.34B | $5.91B | $5.83B | $5.63B | $5.62B | $5.65B | · | $5.21B | $5.33B | $5.33B | · | $4.75B | |
| PP&E (Net) | $547M | $516M | $533M | $525M | $536M | $533M | $535M | $513M | $503M | $513M | · | $498M | $510M | $520M | · | $507M | |
| PP&E (Gross) | · | · | $1.44B | · | · | · | $1.35B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $905M | · | · | · | $819M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $16.60B | $16.54B | $16.62B | $15.95B | $15.61B | $15.03B | $14.71B | $15.09B | $14.48B | $14.52B | $14.57B | $14.29B | $14.18B | $14.02B | $13.92B | $13.18B | |
| Intangibles | $4.75B | $4.80B | $4.96B | $4.71B | $4.60B | $4.50B | $4.50B | $4.73B | $4.61B | $4.72B | · | $4.91B | $4.94B | $4.76B | · | $4.72B | |
| Total Assets | $29.88B | $29.68B | $29.94B | $28.73B | $28.63B | $27.32B | $26.90B | $27.18B | $26.40B | $26.57B | · | $25.98B | $26.04B | $25.74B | · | $24.22B | |
| Accrued Liabilities | · | · | $2.97B | · | · | · | $2.95B | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $8.81B | $8.33B | $8.34B | $8.51B | $7.57B | $7.18B | $6.96B | $6.99B | $6.62B | $6.45B | · | $6.59B | $6.54B | $6.66B | · | $5.25B | |
| Capital Leases | $242M | $232M | $225M | $233M | $210M | $177M | $173M | $188M | $192M | $204M | · | $217M | $242M | $255M | · | $259M | |
| Deferred Tax | $173M | $159M | $179M | $207M | $216M | $197M | $196M | $128M | $149M | $164M | · | $365M | $367M | $421M | · | $560M | |
| Other Non-current Liabilities | $645M | $617M | $688M | $698M | $671M | $676M | $668M | $612M | $632M | $595M | · | $679M | $703M | $641M | · | $561M | |
| Total Liabilities | $23.58B | $23.33B | $23.31B | $22.44B | $22.85B | $21.34B | $20.83B | $20.21B | $19.68B | $20.23B | · | $20.17B | $20.29B | $19.81B | · | $18.88B | |
| Long-term Debt | $16.00B | $15.83B | $15.72B | $14.96B | $15.49B | $14.33B | $13.98B | $13.51B | $13.26B | $13.54B | · | $13.63B | $13.78B | $13.18B | · | $12.39B | |
| Total Debt | $16.00B | $15.83B | · | $14.96B | $15.49B | $14.33B | · | $13.51B | $13.26B | $13.54B | · | $13.63B | $13.78B | $13.18B | · | $12.39B | |
| Retained Earnings | $7.96B | $7.70B | $7.42B | $6.91B | $6.58B | $6.31B | $6.07B | $5.63B | $5.34B | $4.98B | · | $4.22B | $3.92B | $3.62B | · | $3.11B | |
| Treasury Stock | $12.32B | $11.91B | $11.36B | $11.14B | $11.14B | $10.53B | $10.10B | $8.94B | $8.74B | $8.74B | · | $8.51B | $8.36B | $7.87B | · | $7.71B | |
| AOCI | $-964M | $-968M | $-943M | $-928M | $-882M | $-978M | $-1.04B | $-826M | $-949M | $-911M | · | $-903M | $-760M | $-731M | · | $-898M | |
| Stockholders' Equity | $6.17B | $6.22B | $6.50B | $6.16B | $5.78B | $5.98B | $6.07B | $6.97B | $6.71B | $6.34B | · | $5.80B | $5.75B | $5.93B | $5.76B | $5.35B | |
| Liabilities + Equity | $29.88B | $29.68B | $29.94B | $28.73B | $28.63B | $27.32B | $26.90B | $27.18B | $26.40B | $26.57B | · | $25.98B | $26.04B | $25.74B | · | $24.22B | |
| Shares Outstanding | 164,600,000 | 166,900,000 | 169,600,000 | 170,300,000 | 170,000,000 | 174,100,000 | 176,100,000 | 181,600,000 | 182,300,000 | 182,200,000 | 257,200,000 | 182,500,000 | 183,100,000 | 185,500,000 | 256,400,000 | 185,800,000 |
Грошовий потік 14
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $292M | $288M | $317M | $286M | $276M | $265M | $303M | $278M | $269M | $264M | $316M | $297M | $259M | $253M | $357M | $248M | |
| Stock-based Comp | $95M | $65M | $60M | $55M | $60M | $72M | $48M | $54M | $48M | $56M | $45M | $47M | $50M | $75M | $58M | $61M | |
| Deferred Tax | $-36M | $-38M | $-48M | $-46M | $-45M | $-41M | $-15M | $-34M | $-14M | $-66M | $-152M | $-47M | $-43M | $-27M | $-63M | $-24M | |
| Restructuring | $63M | $51M | $24M | $20M | $32M | $29M | $-4M | $28M | $28M | $15M | $17M | $30M | $20M | $17M | $13M | $4M | |
| Other Non-cash | · | $29M | · | · | · | $23M | · | · | · | $-20M | · | · | · | $-173M | · | · | |
| Operating Cash Flow | $558M | $618M | $735M | $908M | $443M | $568M | $885M | $721M | $588M | $522M | $747M | $583M | $402M | $417M | $560M | $863M | |
| CapEx | $198M | $127M | $174M | $136M | $151M | $142M | $164M | $150M | $143M | $145M | $179M | $146M | $160M | $164M | $171M | $165M | |
| Investing Cash Flow | $-381M | $-196M | $-1.10B | $-550M | $-346M | $-305M | $-310M | $-599M | $-221M | $-314M | $-212M | $-573M | $-596M | $-222M | $-477M | $-717M | |
| Stock Repurchased | $398M | $552M | $212M | $0 | $657M | $375M | $1.15B | $200M | $0 | $0 | $229M | $144M | $490M | $129M | $65M | $210M | |
| Net Stock Activity | · | $-552M | · | · | · | $-375M | · | · | · | $0 | · | · | · | $-129M | · | · | |
| Financing Cash Flow | $-214M | $-433M | $535M | $-572M | $145M | $-258M | $-375M | $-137M | $-260M | $-106M | $-420M | $-144M | $95M | $87M | $-193M | $-251M | |
| Net Change in Cash | $-38M | $-33M | $166M | $-225M | $299M | $38M | $130M | $27M | $101M | $68M | $152M | $-158M | $-112M | $278M | $-58M | $-154M | |
| Free Cash Flow | · | $491M | · | · | · | $426M | · | · | · | $377M | · | · | · | $253M | · | · | |
| Levered FCF | · | $334M | · | · | · | $292M | · | · | · | $235M | · | · | · | $140M | · | · |
Прибутковість 8
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | · | · | 23.5% | 22.6% | 22.1% | · | 23.1% | 22.8% | 22.0% | · | 22.8% | |
| Operating Margin | 11.6% | 12.4% | · | 13.5% | 12.6% | 13.0% | · | 14.1% | 13.6% | 13.5% | · | 12.9% | 14.1% | 12.9% | · | 13.2% | |
| Net Margin | 5.9% | 6.6% | · | 8.1% | 6.6% | 6.5% | · | 7.3% | 9.5% | 7.7% | · | 8.1% | 8.0% | 7.9% | · | 7.9% | |
| Pretax Margin | 6.9% | 7.9% | · | 10.0% | 8.0% | 8.4% | · | 9.0% | 11.4% | 9.1% | · | 9.3% | 10.1% | 9.9% | · | 10.1% | |
| EBITDA Margin | 18.3% | 19.3% | · | 20.5% | 19.5% | 19.9% | · | 21.2% | 20.7% | 20.6% | · | 20.8% | 21.0% | 19.8% | · | 20.2% | |
| ROA | 0.88% | 0.96% | · | 1.2% | 0.97% | 0.92% | · | 1.1% | 1.4% | 1.1% | · | 1.2% | 1.2% | 1.1% | · | 1.2% | |
| ROE | 4.3% | 4.5% | · | 5.0% | 4.3% | 4.0% | · | 4.5% | 5.8% | 4.7% | · | 5.4% | 5.3% | 4.9% | · | 5.1% | |
| ROIC | 1.8% | 1.9% | · | 2.1% | 2.0% | 2.0% | · | 2.2% | 2.2% | 2.2% | · | 2.1% | 2.1% | 2.0% | · | 2.1% |
Ліквідність та платоспроможність 5
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.7 | 0.7 | · | 0.7 | 0.8 | 0.8 | · | 0.8 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.8 | · | 0.9 | |
| Quick Ratio | 0.6 | 0.7 | · | 0.6 | 0.7 | 0.7 | · | 0.7 | 0.7 | 0.8 | · | 0.7 | 0.7 | 0.7 | · | 0.8 | |
| Debt / Equity | 2.6 | 2.5 | · | 2.4 | 2.7 | 2.4 | · | 1.9 | 2.0 | 2.1 | · | 2.3 | 2.4 | 2.2 | · | 2.3 | |
| LT Debt / Equity | 2.2 | 2.2 | · | 2.1 | 2.5 | 2.2 | · | 1.8 | 1.8 | 2.0 | · | 2.1 | 2.2 | 2.0 | · | 2.3 | |
| Interest Coverage | 2.6 | 2.7 | · | 2.9 | 2.8 | 3.0 | · | 3.2 | 3.2 | 3.0 | · | 2.7 | 3.1 | 3.3 | · | 4.4 |
Ефективність 2
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.2 | 1.1 | · | 1.2 | 1.2 | 1.2 | · | 1.3 | 1.3 | 1.3 | · | 1.4 |
Оцінка (TTM) 13
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $16.64B | $16.10B | · | $15.84B | $15.56B | $15.28B | · | $15.18B | $15.02B | $14.85B | · | $14.68B | $14.48B | $14.32B | · | $14.06B | |
| Net Income TTM | $1.13B | $1.12B | · | $1.13B | $1.16B | $1.19B | · | $1.24B | $1.25B | $1.18B | · | $1.17B | $1.12B | $1.15B | · | $1.12B | |
| Market Cap | $31.80B | $28.46B | · | $32.35B | $26.79B | $30.69B | · | $43.03B | $38.55B | $46.08B | · | $35.91B | $41.16B | $36.89B | · | $33.66B | |
| Enterprise Value | $45.72B | $42.19B | · | $45.33B | $40.09B | $43.15B | · | $54.83B | $50.13B | $58.04B | · | $48.21B | $53.44B | $48.47B | · | $44.69B | |
| P/E | 29.2 | 26.3 | · | 29.6 | 24.4 | 27.2 | · | 35.3 | 31.3 | 40.1 | · | 31.5 | 37.8 | 32.9 | · | 31.0 | |
| P/S | 1.9 | 1.8 | · | 2.0 | 1.7 | 2.0 | · | 2.8 | 2.6 | 3.1 | · | 2.4 | 2.8 | 2.6 | · | 2.4 | |
| P/B | 5.2 | 4.6 | · | 5.3 | 4.6 | 5.1 | · | 6.2 | 5.7 | 7.3 | · | 6.2 | 7.2 | 6.2 | · | 6.3 | |
| P / Cash Flow | · | 46.1 | · | · | · | 54.0 | · | · | · | 88.3 | · | · | · | 88.5 | · | · | |
| P / FCF | · | 58.0 | · | · | · | 72.1 | · | · | · | 122.2 | · | · | · | 145.8 | · | · | |
| EV / EBITDA | 57.3 | 52.6 | · | 54.0 | 51.3 | 56.7 | · | 66.2 | 63.5 | 75.4 | · | 62.0 | 68.3 | 67.0 | · | 62.1 | |
| EV / FCF | · | 85.9 | · | · | · | 101.3 | · | · | · | 153.9 | · | · | · | 191.6 | · | · | |
| EV / Revenue | 2.7 | 2.6 | · | 2.9 | 2.6 | 2.8 | · | 3.6 | 3.3 | 3.9 | · | 3.3 | 3.7 | 3.4 | · | 3.2 | |
| Earnings Yield | 3.4% | 3.8% | · | 3.4% | 4.1% | 3.7% | · | 2.8% | 3.2% | 2.5% | · | 3.2% | 2.6% | 3.0% | · | 3.2% |
Фінансова звітність Звіт про прибутки та збитки, баланс, рух грошових коштів — річні, за останні 5 років
Звіт про прибутки та збитки
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Виручка | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B |
| Операційна маржа % | 13.4% | 14.3% | 13.2% | 12.5% | 10.0% |
| Чистий прибуток | $1.36B | $1.37B | $1.36B | $1.09B | $966M |
| Розбавлений EPS | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 |
Баланс
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Борг / Власний капітал | 2.4 | 2.3 | 2.2 | 2.2 | 2.0 |
| Поточний коефіцієнт | 0.7 | 0.8 | 0.9 | 0.9 | 0.9 |
| Коефіцієнт швидкої ліквідності | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 |
Грошовий потік
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Вільний грошовий потік | $2.05B | $2.11B | $1.50B | $1.59B | $2.30B |
Останні новини Останні заголовки, що згадують цю компанію
Мої показники Ваш персональний список спостереження — вибрані рядки з Повних фундаментальних даних
Виберіть показники, які для вас важливі — натисніть ➕ поруч із будь-яким рядком у Повних фундаментальних даних вище.
Ваш вибір збережено і він буде застосовуватися до всіх тікерів.
Інституційні власники (13F) 1 176 подавачів звітності · $16.9B всього · Станом на 30 червня 2026 р.
Інституційні інвестори, які звітують про володіння цими акціями у своїй квартальній формі SEC 13F. Тільки довгі позиції; один подавець звітності може з'явитися двічі для окремих опціонних контрактів. Великі протилежні опціонні позиції (пут/кол) зазвичай відображають маркет-мейкінг або хеджування запасів, а не спрямованість переконань.
| Нові позиції | Закриті позиції | Збільшено | Зменшено | Зміна чистих акцій |
|---|---|---|---|---|
| 132 (-13 проти попереднього кв.) | 103 (-63 проти попереднього кв.) | 388 (-16 проти попереднього кв.) | 420 (+23 проти попереднього кв.) | -3.2M |
Порівняно з Q1 2026. Звіти SEC Form 13F подаються протягом 45 днів після закінчення кварталу плюс невеликий буфер для тих, хто подає із запізненням — квартали, що ще знаходяться в цьому вікні, пропускаються на користь останньої повністю звітної пари.
| Інституційний інвестор | Вартість | Акції | % від відстежуваного 13F | Тип |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $2 107 074 341 | 10 905 053 | 12,50% | Акції |
| STATE STREET CORP | $1 450 742 906 | 7 508 244 | 8,61% | Акції |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1 449 535 087 | 7 501 993 | 8,60% | Акції |
| Artisan Partners Limited Partnership | $916 526 317 | 4 743 434 | 5,44% | Акції |
| GEODE CAPITAL MANAGEMENT, LLC | $751 515 288 | 3 907 352 | 4,46% | Акції |
| NORGES BANK | $437 632 480 | 2 264 944 | 2,60% | Акції |
| Longview Partners (Guernsey) LTD | $289 976 847 | 1 500 760 | 1,72% | Акції |
| DIMENSIONAL FUND ADVISORS LP | $282 111 725 | 1 460 055 | 1,67% | Акції |
| ALLIANCEBERNSTEIN L.P. | $280 214 615 | 1 643 102 | 1,66% | Акції |
| LYRICAL ASSET MANAGEMENT LP | $243 436 719 | 1 259 894 | 1,44% | Акції |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $241 535 241 | 1 250 053 | 1,43% | Акції |
| CANADA PENSION PLAN INVESTMENT BOARD | $240 910 560 | 1 246 820 | 1,43% | Акції |
| AMERICAN CENTURY COMPANIES INC | $204 721 978 | 1 059 526 | 1,21% | Акції |
| LAZARD ASSET MANAGEMENT LLC | $188 339 728 | 974 742 | 1,12% | Акції |
| VANGUARD FIDUCIARY TRUST CO | $181 113 608 | 937 344 | 1,07% | Акції |
| Sumitomo Mitsui Trust Group, Inc. | $160 725 420 | 831 826 | 0,95% | Акції |
| CADIAN CAPITAL MANAGEMENT, LP | $157 619 601 | 815 752 | 0,94% | Акції |
| FIL Ltd | $153 554 253 | 794 712 | 0,91% | Акції |
| JARISLOWSKY, FRASER Ltd | $149 227 880 | 785 658 | 0,89% | Акції |
| GREENHAVEN ASSOCIATES INC | $148 401 655 | 768 045 | 0,88% | Акції |
| 1832 Asset Management L.P. | $143 802 826 | 744 244 | 0,85% | Акції |
| AMERIPRISE FINANCIAL INC | $142 211 800 | 735 972 | 0,84% | Акції |
| FMR LLC | $135 375 060 | 700 627 | 0,80% | Акції |
| Balyasny Asset Management L.P. | $135 333 607 | 700 412 | 0,80% | Акції |
| Boston Partners | $133 444 690 | 690 636 | 0,79% | Акції |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $121 523 014 | 628 936 | 0,72% | Акції |
| ENVESTNET ASSET MANAGEMENT INC | $113 104 610 | 585 374 | 0,67% | Акції |
| RAYMOND JAMES FINANCIAL INC | $106 359 117 | 550 456 | 0,63% | Акції |
| EARNEST PARTNERS LLC | $105 901 563 | 548 088 | 0,63% | Акції |
| MILLENNIUM MANAGEMENT LLC | $99 841 411 | 516 724 | 0,59% | Акції |
| Swiss National Bank | $92 490 550 | 478 680 | 0,55% | Акції |
| BlackRock, Inc. | $91 938 713 | 475 824 | 0,55% | Акції |
| CIBC Bancorp USA Inc. | $91 205 076 | 471 352 | 0,54% | Акції |
| D. E. Shaw & Co., Inc. | $90 085 733 | 466 234 | 0,53% | Акції |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $79 369 559 | 410 773 | 0,47% | Акції |
| Mitsubishi UFJ Asset Management Co., Ltd. | $78 508 764 | 406 318 | 0,47% | Акції |
| National Pension Service | $72 645 503 | 375 973 | 0,43% | Акції |
| Ilex Capital Partners (UK) LLP | $71 680 176 | 370 977 | 0,43% | Акції |
| BNP PARIBAS FINANCIAL MARKETS | $70 949 418 | 367 195 | 0,42% | Акції |
| California Public Employees Retirement System | $70 656 690 | 365 680 | 0,42% | Акції |
| Vanguard Global Advisers, LLC | $69 529 444 | 359 846 | 0,41% | Акції |
| Quantinno Capital Management LP | $69 138 831 | 357 824 | 0,41% | Акції |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $68 883 914 | 356 505 | 0,41% | Акції |
| Legal & General Group Plc | $67 679 555 | 350 272 | 0,40% | Акції |
| Assenagon Asset Management S.A. | $65 786 773 | 340 476 | 0,39% | Акції |
| CI INVESTMENTS INC. | $65 379 079 | 338 366 | 0,39% | Акції |
| VANGUARD ASSET MANAGEMENT, Ltd | $64 474 036 | 333 682 | 0,38% | Акції |
| RHUMBLINE ADVISERS | $64 175 589 | 332 138 | 0,38% | Акції |
| LAKEWOOD CAPITAL MANAGEMENT, LP | $61 424 638 | 317 900 | 0,36% | Акції |
| Capital World Investors | $61 228 906 | 316 887 | 0,36% | Акції |
| FIRST MANHATTAN CO. LLC. | $60 389 365 | 312 542 | 0,36% | Акції |
| Man Group plc | $57 113 707 | 295 589 | 0,34% | Акції |
| Cornerstone Investment Partners, LLC | $56 162 291 | 290 665 | 0,33% | Акції |
| Point72 Asset Management, L.P. | $53 998 807 | 279 468 | 0,32% | Акції |
| Qube Research & Technologies Ltd | $53 924 997 | 279 086 | 0,32% | Акції |
| Vulcan Value Partners, LLC | $50 209 376 | 259 856 | 0,30% | Акції |
| GOLDMAN SACHS GROUP INC | $47 369 345 | 245 158 | 0,28% | Акції |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $44 584 443 | 261 431 | 0,26% | Акції |
| Danica Pension, Livsforsikringsaktieselskab | $43 968 177 | 227 555 | 0,26% | Акції |
| SEB Asset Management AB | $41 578 752 | 215 189 | 0,25% | Акції |
| COUNTRY TRUST BANK | $41 040 701 | 212 404 | 0,24% | Акції |
| BANK OF AMERICA CORP /DE/ | $40 135 272 | 207 718 | 0,24% | Акції |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $39 462 000 | 204 232 | 0,23% | Акції |
| Associated Banc-Corp | $38 755 873 | 200 579 | 0,23% | Акції |
| Freestone Grove Partners LP | $38 705 830 | 200 320 | 0,23% | Акції |
| ASSETMARK, INC | $38 066 693 | 197 012 | 0,23% | Акції |
| Trajan Wealth LLC | $35 265 548 | 182 515 | 0,21% | Акції |
| Robeco Institutional Asset Management B.V. | $33 903 348 | 175 465 | 0,20% | Акції |
| HARRIS ASSOCIATES L P | $33 507 826 | 173 418 | 0,20% | Акції |
| UBS Group AG | $32 389 275 | 167 629 | 0,19% | Акції |
| Dana Investment Advisors, Inc. | $32 065 825 | 165 955 | 0,19% | Акції |
| Woodline Partners LP | $31 980 808 | 165 515 | 0,19% | Акції |
| KENSICO CAPITAL MANAGEMENT CORP | $31 881 300 | 165 000 | 0,19% | Акції |
| PANAGORA ASSET MANAGEMENT INC | $30 940 319 | 160 130 | 0,18% | Акції |
| BARCLAYS PLC | $30 871 145 | 159 772 | 0,18% | Акції |
| Act Two Investors LLC | $30 672 902 | 158 746 | 0,18% | Акції |
| AVIVA PLC | $29 357 847 | 151 940 | 0,17% | Акції |
| MML INVESTORS SERVICES, LLC | $28 789 342 | 148 998 | 0,17% | Акції |
| Meridiem Capital Partners LP | $27 945 409 | 144 630 | 0,17% | Акції |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $27 653 453 | 143 119 | 0,16% | Акції |
| Gotham Asset Management, LLC | $27 184 508 | 140 692 | 0,16% | Акції |
| LPL Financial LLC | $26 931 587 | 139 383 | 0,16% | Акції |
| Candriam S.C.A. | $26 917 640 | 139 445 | 0,16% | Акції |
| CIBC Asset Management Inc | $26 395 011 | 136 606 | 0,16% | Акції |
| Howard Capital Management Group, LLC | $26 033 014 | 134 733 | 0,15% | Акції |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $25 336 358 | 131 127 | 0,15% | Акції |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24 914 763 | 128 620 | 0,15% | Акції |
| Banco Santander, S.A. | $23 956 575 | 123 986 | 0,14% | Акції |
| MORGAN STANLEY | $23 730 050 | 122 813 | 0,14% | Акції |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23 514 874 | 121 700 | 0,14% | Опціон пут |
| TUDOR INVESTMENT CORP ET AL | $23 098 292 | 119 544 | 0,14% | Акції |
| Compagnie Lombard Odier SCmA | $22 951 639 | 118 785 | 0,14% | Акції |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $22 870 437 | 134 106 | 0,14% | Акції |
| Cetera Investment Advisers | $22 677 210 | 117 365 | 0,13% | Акції |
| Artemis Investment Management LLP | $22 412 167 | 115 993 | 0,13% | Акції |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $22 184 748 | 114 816 | 0,13% | Акції |
| VAN ECK ASSOCIATES CORP | $21 593 301 | 111 755 | 0,13% | Акції |
| Andra AP-fonden | $20 704 409 | 121 405 | 0,12% | Акції |
| GDS Wealth Management | $20 556 096 | 106 387 | 0,12% | Акції |
| Parkman Healthcare Partners LLC | $20 444 801 | 105 811 | 0,12% | Акції |
Інсайдери компанії 31 інсайдер · 14 керівники · 16 директори
| Інсайдер | Роль | Остання активність | Кількість акцій у власності | Купівлі за 12 міс. | Продажі за 12 міс. | Нетто 12 міс |
|---|---|---|---|---|---|---|
| Ari Bousbib | Chairman, Chief Executive Officer & President Power of Attorney | 29 липня 2026 р. M | 835 941 | 0 | 10 | $-38 553 192 |
| Michael R. Mcdonnell | EVP and CFO | 03 жовтня 2016 р. A | 44 106 | 0 | 0 | $0 |
| Richard W Staub | President, Research & Development Solutions Power of Attorney | 03 серпня 2026 р. S | 13 312 | 0 | 1 | $-1 279 740 |
| Bhavik Patel | President, MedTech and Consumer Health Power of Attorney | 31 липня 2026 р. S | 1 348 | 0 | 1 | $-436 426 |
| John D Ratliff | President and COO | 18 листопада 2013 р. X | 0 | 0 | 0 | $0 |
| Kevin K Gordon | EVP and COO | 09 червня 2016 р. X | 17 899 | 0 | 0 | $0 |
| Keriann Cherofsky | SVP, Corporate Controller Power of Attorney | 29 липня 2026 р. S | 2 989 | 0 | 1 | $-136 827 |
| Eric Sherbet | Executive Vice President, General Counsel Power of Attorney | 29 липня 2026 р. S | 20 999 | 0 | 1 | $-1 245 800 |
| Iii James H Erlinger | Exec VP and GC | 03 жовтня 2016 р. A | 18 024 | 0 | 0 | $0 |
| Thomas Pike | Vice Chair, Pres R&D Solutions | 03 жовтня 2016 р. A | 185 460 | 0 | 0 | $0 |
| Kevin C Knightly | Pres Info & Tech Solutions | 03 жовтня 2016 р. A | 26 826 | 0 | 0 | $0 |
| Charles Edward Williams | Sr VP and Controller | 03 березня 2016 р. A | 3 911 | 0 | 0 | $0 |
| Derek M. Winstanly | Exec VP & Chief Cust & Gov Ofc | 13 лютого 2014 р. X | 229 500 | 0 | 0 | $0 |
| Michael I. Mortimer | Exec VP & Chief Admin Officer | 18 листопада 2013 р. S | 25 000 | 0 | 0 | $0 |
| Morris Leslie Wims | Директор | 14 липня 2026 р. A | — | 0 | 0 | $0 |
| Jim Fasano | Директор | 14 липня 2026 р. A | — | 0 | 0 | $0 |
| Colleen A Goggins | Директор | 14 липня 2026 р. A | — | 0 | 0 | $0 |
| John G Danhakl | Директор | 14 липня 2026 р. A | 0 | 0 | 0 | $0 |
| John Connaughton | Директор | 02 грудня 2021 р. G | 0 | 0 | 0 | $0 |
| Dennis B Ph D Gillings | Директор | 28 серпня 2017 р. S | 84 067 | 0 | 0 | $0 |
| Ronald A Rittenmeyer | Директор | 03 жовтня 2016 р. A | 54 849 | 0 | 0 | $0 |
| Annie H. Lo | Директор | 12 травня 2016 р. P | 2 062 | 0 | 0 | $0 |
| John M. Leonard | Директор | 05 травня 2016 р. A | 2 316 | 0 | 0 | $0 |
| Michael J Evanisko | Директор | 05 травня 2016 р. A | 5 346 | 0 | 0 | $0 |
| Jack M Greenberg | Директор | 05 травня 2016 р. A | 2 930 | 0 | 0 | $0 |
| Leonard D Schaeffer | Директор | 05 травня 2016 р. A | 65 896 | 0 | 0 | $0 |
| Christopher R Gordon | Директор | 05 серпня 2015 р. S | 9 944 017 | 0 | 0 | $0 |
| Mireille Gillings | Директор | 19 травня 2015 р. X | 11 663 929 | 0 | 0 | $0 |
| Canada Pension Plan Investment Board | Власник 10% | 18 вересня 2018 р. J | 1 569 600 | 0 | 0 | $0 |
| DENNIS & MIREILLE GILLINGS FOUNDATION | Власник 10% | 19 травня 2015 р. S | 103 556 | 0 | 0 | $0 |
| Gillings Limited Partnership | Власник 10% | 10 листопада 2014 р. S | 0 | 0 | 0 | $0 |
Інсайдери згідно з формами SEC 3/4/5; чистий результат = лише відкритий ринок купівлі/продажу
Активісти та власники %+ 5 4 холдинги
Інвестори, які подали Розклад SEC 13D — бенефіціарна власність понад 5% з наміром вплинути на емітента (активістські частки, кампанії в раді директорів, M&A). Кожен рядок показує останній відомий стан позиції цього подавця.
| Подавець | Подано | Частка | Статус | Мета | Подача |
|---|---|---|---|---|---|
| Canada Pension Plan Investment Board, CPP Investment Board Private Holdings Inc. ×8 подання | 13 серпня 2019 р. | — | Первинна подача | — | SEC |
| TPG Group Holdings (SBS) Advisors, Inc., TPG Advisors VI, Inc., TPG Advisors V, Inc., TPG Biotech Advisors, Inc., David Bonderman, James G. Coulter ×9 подання | 12 березня 2019 р. | — | Первинна подача | Структура капіталу | SEC |
| Quintiles Transnational Holdings Inc. | 13 травня 2016 р. | — | Первинна подача | M&A / продаж | SEC |
| OR | 13 травня 2016 р. | — | Первинна подача | M&A / продаж | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Присутність в ETF Належить 171 ETF
Вага відображає лише прямі акціонерні володіння (N-PORT); фонди з кредитним плечем або похідними інструментами можуть мати додаткову експозицію за свопами, яка не відображається.
| Фонд | Вага | Одиниці | Станом на | Джерело |
|---|---|---|---|---|
| HEAL · Global X Funds | 4,72% | 6 483 NS | 31 травня 2026 р. | N-PORT |
| BSJQ · Invesco Exchange-Traded Self-Indexe… | 3,06% | 24 765 000 | 19 серпня 2026 р. | Щоденно |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,97% | 64 938 SH | 19 серпня 2026 р. | Щоденно |
| FLV · AMERICAN CENTURY ETF TRUST | 1,91% | 37 019 NS | 31 травня 2026 р. | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,77% | 13 993 SH | 19 серпня 2026 р. | Щоденно |
| RUNN · Strategic Trust | 1,75% | 33 257 NS | 31 травня 2026 р. | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,73% | 5 832 NS | 30 квітня 2026 р. | N-PORT |
| EPMB · Harbor ETF Trust | 1,57% | 447 NS | 30 квітня 2026 р. | N-PORT |
| EPMV · Harbor ETF Trust | 1,36% | 380 NS | 30 квітня 2026 р. | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1,03% | 726 NS | 30 квітня 2026 р. | N-PORT |
| LRGC · AB Active ETFs, Inc. | 0,89% | 60 947 NS | 31 травня 2026 р. | N-PORT |
| NUMV · Nushares ETF Trust | 0,83% | 22 672 NS | 30 квітня 2026 р. | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,80% | 44 382 NS | 30 квітня 2026 р. | N-PORT |
| RFFC · ALPS ETF Trust | 0,75% | 1 218 NS | 31 травня 2026 р. | N-PORT |
| IYH · iShares Trust | 0,63% | 97 973 SH | 19 серпня 2026 р. | Щоденно |
| COWZ · Pacer Funds Trust | 0,62% | 709 284 NS | 30 квітня 2026 р. | N-PORT |
| QQWZ · Pacer Funds Trust | 0,62% | 1 821 NS | 30 квітня 2026 р. | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0,56% | 1 072 113 SH | 19 серпня 2026 р. | Щоденно |
| ITAN · EA Series Trust | 0,55% | 2 710 NS | 29 травня 2026 р. | N-PORT |
| IMCV · iShares Trust | 0,55% | 26 899 SH | 19 серпня 2026 р. | Щоденно |
| IXJ · iShares Trust | 0,49% | 87 526 SH | 19 серпня 2026 р. | Щоденно |
| VHT · VANGUARD WORLD FUND | 0,48% | 510 171 SH | 19 серпня 2026 р. | Щоденно |
| RXL · ProShares Trust | 0,45% | 1 768 NS | 31 травня 2026 р. | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,44% | 78 509 NS | 30 квітня 2026 р. | N-PORT |
| REVS · Columbia ETF Trust I | 0,40% | 7 214 NS | 30 квітня 2026 р. | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,39% | 3 383 NS | 30 квітня 2026 р. | N-PORT |
| IWS · iShares Trust | 0,38% | 249 871 SH | 19 серпня 2026 р. | Щоденно |
| EVUS · iShares Trust | 0,34% | 5 323 SH | 19 серпня 2026 р. | Щоденно |
| VO · VANGUARD INDEX FUNDS | 0,31% | 3 616 975 SH | 19 серпня 2026 р. | Щоденно |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,30% | 8 582 000 | 19 серпня 2026 р. | Щоденно |
| SUSA · iShares Trust | 0,30% | 50 864 SH | 19 серпня 2026 р. | Щоденно |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,29% | 6 499 NS | 31 травня 2026 р. | N-PORT |
| IWR · iShares Trust | 0,28% | 677 678 SH | 19 серпня 2026 р. | Щоденно |
| IMCB · iShares Trust | 0,27% | 19 156 SH | 19 серпня 2026 р. | Щоденно |
| SIZE · iShares Trust | 0,25% | 4 598 SH | 19 серпня 2026 р. | Щоденно |
| RSP · Invesco Exchange-Traded Fund Trust | 0,25% | 1 023 110 SH | 19 серпня 2026 р. | Щоденно |
| EUSA · iShares, Inc. | 0,24% | 19 768 SH | 19 серпня 2026 р. | Щоденно |
| PY · Principal Exchange-Traded Funds | 0,23% | 2 572 NS | 30 червня 2026 р. | N-PORT |
| SPXD · DBX ETF Trust | 0,22% | 81 NS | 31 травня 2026 р. | N-PORT |
| XOEF · iShares Trust | 0,22% | 209 SH | 19 серпня 2026 р. | Щоденно |
| DFLV · Dimensional ETF Trust | 0,21% | 79 706 NS | 30 квітня 2026 р. | N-PORT |
| RECS · Columbia ETF Trust I | 0,21% | 72 385 NS | 30 квітня 2026 р. | N-PORT |
| GSEW · Goldman Sachs ETF Trust | 0,20% | 19 216 NS | 31 травня 2026 р. | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,18% | 4 875 NS | 30 квітня 2026 р. | N-PORT |
| OALC · Unified Series Trust | 0,16% | 2 166 NS | 31 травня 2026 р. | N-PORT |
| USXF · iShares Trust | 0,16% | 9 891 SH | 19 серпня 2026 р. | Щоденно |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,16% | 12 884 NS | 30 квітня 2026 р. | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,16% | 180 000 | 19 серпня 2026 р. | Щоденно |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,15% | 14 406 NS | 30 квітня 2026 р. | N-PORT |
| IETC · iShares U.S. ETF Trust | 0,15% | 4 304 SH | 19 серпня 2026 р. | Щоденно |